Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

694.99 +13.27 (+1.95%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,505,341
Open 683.00
Bid (Size) 697.00 (40)
Ask (Size) 699.99 (40)
Prev. Close 681.72
Today's Range 679.93 - 713.58
52wk Range 476.49 - 823.56
Shares Outstanding 91,779,465
Dividend Yield 0.25%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
What's going on in today's session: S&P500 movers ↗
Let's have a look at the top S&P500 gainers and losers one hour before the close of the markets of today's session. 
Via Chartmill
News headline image
Tech Sector Tremors: Is the AI Bubble Deflating, and What's Next for the Market?
As of mid-November 2025, a palpable unease has settled over the technology sector, long the darling of investors and the primary engine of market growth. After a period of unprecedented outperformance,... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks

Performance

YTD
-2.8%
-2.8%
1 Month
+21.4%
+21.4%
3 Month
+22.8%
+22.8%
6 Month
+18.8%
+18.8%
1 Year
-13.6%
-13.6%

More News

Read More
News headline image
Wall Street Falls On US Government Reopening Day, Bitcoin Slides To $100,000: What's Moving Markets Thursday? ↗
Via Benzinga
Topics Economy
News headline image
Explore the top gainers and losers within the S&P500 index in today's session. ↗
Via Chartmill
News headline image
Regeneron Highlights Progress at American Society of Hematology (ASH), with Updated Data in Multiple Myeloma, Lymphoma and Paroxysmal Nocturnal Hemoglobinuria Programs
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Here Are the Top Growth Healthcare Stocks Every New Investor Should Know ↗
Via The Motley Fool
News headline image
CRISPR Therapeutics' Investigational Gene Therapy Shows Promising Lipid-Lowering Effects In Early Trial ↗
Via Benzinga
News headline image
Incyte (NASDAQ:INCY) Q3 Earnings: Leading The Immuno-Oncology Pack
Via StockStory
Topics Artificial Intelligence
News headline image
Winners And Losers Of Q3: Regeneron (NASDAQ:REGN) Vs The Rest Of The Immuno-Oncology Stocks
Via StockStory
Topics Artificial Intelligence
News headline image
Merck Takes On Amgen, Regeneron, Lowering Stubbornly High Cholesterol By 60% ↗
Via Investor's Business Daily
News headline image
Phase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor XI Antibodies Presented at American Heart Association Scientific Sessions and Published in The Lancet
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Dupixent® (dupilumab) Pivotal Trial Met All Primary and Secondary Endpoints, Reducing Signs and Symptoms of Allergic Fungal Rhinosinusitis (AFRS); sBLA Accepted for FDA Priority Review
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years ↗
Via Benzinga
News headline image
Looking Into Regeneron Pharmaceuticals Inc's Recent Short Interest ↗
Via Benzinga
News headline image
The Shadow of Doubt: Why Investors Are 'Taking Fright' as Markets Brace for Reality
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
5 Revealing Analyst Questions From Regeneron’s Q3 Earnings Call
Via StockStory
Topics Earnings
News headline image
Michael Burry Is Super-Bearish On Palantir — With 5 Million Puts ↗
Via Benzinga
News headline image
Regeneron Announces Investor Conference Presentations
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
2 Beaten-Down Stocks That Could Be About to Rally ↗
Via The Motley Fool
News headline image
Dupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
REGN Q3 Deep Dive: Pipeline, Regulatory Progress, and Label Expansion Take Center Stage
Via StockStory
News headline image
Regeneron (REGN) Q3 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Uncover the latest developments among S&P500 stocks in today's session. ↗
Via Chartmill
News headline image
Explore the top gainers and losers within the S&P500 index in today's session. ↗
Via Chartmill
News headline image
Nasdaq 100 Hits 26,000, Gold Falls Below $4,000: What's Moving Markets Tuesday? ↗
Via Benzinga
Topics Economy

Frequently Asked Questions

Is Regeneron Pharmaceuticals publicly traded?
Yes, Regeneron Pharmaceuticals is publicly traded.
What exchange does Regeneron Pharmaceuticals trade on?
Regeneron Pharmaceuticals trades on the Nasdaq Stock Market
What is the ticker symbol for Regeneron Pharmaceuticals?
The ticker symbol for Regeneron Pharmaceuticals is REGN on the Nasdaq Stock Market
What is the current price of Regeneron Pharmaceuticals?
The current price of Regeneron Pharmaceuticals is 694.99
When was Regeneron Pharmaceuticals last traded?
The last trade of Regeneron Pharmaceuticals was at 11/13/25 04:00 PM ET
What is the market capitalization of Regeneron Pharmaceuticals?
The market capitalization of Regeneron Pharmaceuticals is 63.79B
How many shares of Regeneron Pharmaceuticals are outstanding?
Regeneron Pharmaceuticals has 64B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.